Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Emapalumab in HLH
NCT02069899Phase 3Completed
- Sponsor
- Sobi
- Start
- Aug 2014
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of emapalumab in hemophagocytic lymphohistiocytosis (HLH), sponsored by Sobi. Started Aug 2014; status: completed.
02
Drugs
emapalumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT02069899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069899.